NeuroAid (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia

作     者：Kavian Ghandehari Zahra Izadi Mood Saeed Ebrahimzadeh David Picard Yue Zhang 

作者机构：Neuroscience Research Center Mashhad University of Medical Sciences Mashhad Iran P.O. Box 91766-99199 Department of Traditional Medicine Mashhad University of Medical Sciences Mashhad Iran P.O. Box 91766-99199 Department of Biostatistics Mashhad University of Medical Sciences Mashhad Iran P.O. Box 91766-99199 National Neuroscience Institute Singapore Moleac Ltd Helios 09-08 11Biopolis Way Singapore 138667 National Neuroscience Institute Singapore Moleac Ltd Helios 09-08 11Biopolis Way Singapore 138667 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2011年第6卷第6期

页      面：418-422页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

主　　题：MLC601 piracetam post-infarct recovery stroke 

摘      要：In the clinic, the natural recovery rate of homonymous hemianopsia caused by occipital lobe infamtion is low. At present, ideal therapeutic effects of piracetam for improving visual field defects following homonymous hemianopsia do not exist. The present randomized, controlled study compared the effects of NeuroAid （MLC601） versus piracetam for improving visual field defects in post-infarct homonymous hemianopsia patients matched for age and sex. After 3 months of treatment with NeuroAid （MLC601） or piracetam, visual field defects were significantly improved, compared with prior to treatment （P 〈 0.001）. After treatment with MLC601, relative reduction of right and left visual field defects was 45% and 45.7%, respectively, while relative reduction after treatment with piracetam was 32.7% and 30.3%, respectively. These findings suggested that MLC601 was superior to piracetam for reducing visual field defects in homonymous hemianopsia patients.